Characteristics of patients with mediastinal tumors and false-positive or false-negative FDG PET result
| Patient no. . | Age, y . | Therapy and stage . | Mass in control CT . | Site3-150 . | Time until result, mo3-151 . | Biopsy . | Reason . |
|---|---|---|---|---|---|---|---|
| FDG PET false positive | |||||||
| 1 | 25 | 2× COPP/ABVD + RT (IIB) | Stable | Left hilar | 68 | nd | Unknown |
| 2 | 18 | 2× COPP/ABVD + RT (IIA) | Stable | Ventral med | 40 | Negative | Unknown |
| 3 | 32 | 2× COPP/ABVD + RT (IIA) | Stable | Lower med | 40 | nd | Unknown |
| 4 | 18 | 4× BEACOPP esc + 4× BEACOPP bas (IVB) | Regression | Ventral med | 12 | nd | Thymus hyperplasia |
| FDG PET false negative | |||||||
| 5 | 32 | 8× BEACOPP-14 (IIIB) | Mediastinal | 14 | Positive | Late relapse | |
| 6 | 32 | 3× DexaBEAM (1st relapse, med) | Mediastinal | 29 | Positive | Late relapse | |
| 7 | 33 | 8× BEACOPP esc (IVA) | Mediastinal, abdominal | 2 | Positive | Unknown, PET after 2 mo positive | |
| Patient no. . | Age, y . | Therapy and stage . | Mass in control CT . | Site3-150 . | Time until result, mo3-151 . | Biopsy . | Reason . |
|---|---|---|---|---|---|---|---|
| FDG PET false positive | |||||||
| 1 | 25 | 2× COPP/ABVD + RT (IIB) | Stable | Left hilar | 68 | nd | Unknown |
| 2 | 18 | 2× COPP/ABVD + RT (IIA) | Stable | Ventral med | 40 | Negative | Unknown |
| 3 | 32 | 2× COPP/ABVD + RT (IIA) | Stable | Lower med | 40 | nd | Unknown |
| 4 | 18 | 4× BEACOPP esc + 4× BEACOPP bas (IVB) | Regression | Ventral med | 12 | nd | Thymus hyperplasia |
| FDG PET false negative | |||||||
| 5 | 32 | 8× BEACOPP-14 (IIIB) | Mediastinal | 14 | Positive | Late relapse | |
| 6 | 32 | 3× DexaBEAM (1st relapse, med) | Mediastinal | 29 | Positive | Late relapse | |
| 7 | 33 | 8× BEACOPP esc (IVA) | Mediastinal, abdominal | 2 | Positive | Unknown, PET after 2 mo positive | |
RT indicates radiotherapy; med, mediastinum; nd, not done; esc, escalated; bas, basis.
For FDG PET false-positive patients, this is the tumor localization site; for FDG PET false-negative patients, the site of relapse.
For FDG PET false-positive patients, this is the time after there was clinically complete remission with a residual mass; for FDG PET false-negative patients, the time after which there was progressive disease and/or relapse.